DISEASE INDICATIONS: Chronic Obstructive Pulmonary Disease, Asthma
MANUFACTURER: GlaxoSmithKline
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Pharmaceuticals and Medical Devices Agency (PMDA)
It is used for the management of chronic obstructive pulmonary disease (COPD), a chronic respiratory condition characterized by breathing difficulties, coughing, and wheezing. This medication is designed to provide comprehensive treatment for COPD by addressing various aspects of the disease.
DISEASE INDICATIONS: Psoriasis
MANUFACTURER: Janssen Biotech
USAGE: Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA)
Therapeutic Goods Administration (TGA)
Tremfya is a pharmaceutical medication that contains the active ingredient guselkumab. It belongs to a class of medications known as interleukin-23 (IL-23) inhibitors and is primarily used in the treatment of certain chronic skin conditions, particularly moderate to severe plaque psoriasis. Guselkumab works by targeting specific proteins in the immune system that play a role in the development of psoriatic skin lesions, thereby reducing the symptoms associated with this condition.
CHARACTERISTICS
ACTIVE HALF-LIFE 4-6 HOURS
CLASSIFICATION ANABOLIC STEROID
DOSAGE 500-1000 MCG/DAY
ACNE RARELY
WATER RETENTION NO
HBR NO
HEPATOTOXICITY VERY HIGH
AROMATIZATION NO
ACTIVE SUBSTANCE METHYLTRIENOLONE
FORM 50 TABLETS X 1 MG
MANUFACTURER ALPHA PHARMA
CHARACTERISTICS
ACTIVE HALF-LIFE 1-1.5 DAYS
CLASSIFICATION ANABOLIC STEROID
DOSAGE MEN 200-700 MG/WEEK
ACNE RARELY
WATER RETENTION NO
HBR NO
HEPATOTOXICITY YES
AROMATIZATION NO
ACTIVE SUBSTANCE TRENBOLONE ACETATE
FORM 10 ML X 100 MG/ML
MANUFACTURER SIS LABS
